iRhythm Holdings, Inc.

iRhythm Holdings operates in digital cardiac monitoring, developing and commercializing wearable patch-based electrocardiogram (ECG) systems for ambulatory arrhythmia detection in the United States. The company's primary product line is the Zio family of remote monitoring systems, which includes prescription-only patch devices that record continuous cardiac electrical signals for up to 14 days. These devices—the Zio Monitor System, Zio XT System, and Zio AT System—transmit data wirelessly to supporting software platforms that capture and analyze ECG recordings to identify irregular heart rhythms. The Zio AT variant incorporates a wireless gateway component to facilitate connectivity during the patient monitoring period. The company also provides complementary cardiac telemetry services and the Zio ECG Utilization Software System for data analysis.

Revenue is primarily generated through the sale and use of Zio monitoring devices and associated diagnostic services. The company maintains a collaboration agreement with BioIS to develop expanded physiological monitoring capabilities, including pulse oximetry, accelerometry, and non-invasive blood pressure measurement features for integration into its ambulatory cardiac platforms.

The company employs approximately 2,400 full-time staff and operates from its headquarters in San Francisco, California. iRhythm was incorporated in 2006 and is publicly listed on Nasdaq with a market capitalization of $4.3 billion.